Zobrazeno 1 - 10
of 97
pro vyhledávání: '"transplant-eligible"'
Autor:
Mads Harsløf, Iman Chanchiri, Trine Silkjær, Ulf Christian Frølund, Elena Manuela Teodorescu, Kristina Buchardi Nielsen, Per Ishøy Nielsen, Per Trøllund Pedersen, Katrine Fladeland Iversen, Thomas Lund, Kirsten Grønbæk, Sigrun Thorsteinsdottir, Annette Vangsted, Agoston Gyula Szabo
Publikováno v:
eJHaem, Vol 5, Iss 2, Pp 316-324 (2024)
Abstract Lenalidomide maintenance (LM) has shown benefit in progression‐free survival (PFS) and overall survival (OS) in clinical trials. LM is the recommended standard of care in patients with newly diagnosed multiple myeloma (MM) after high‐dos
Externí odkaz:
https://doaj.org/article/9e33690602b2437da6963030afaaa7d7
Autor:
John R. Jones, David A. Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Molly Reed, Mark T. Drayson, Roger G. Owen, Kevin D. Boyd, Gordon Cook, Gareth J. Morgan, Graham H. Jackson
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102099- (2023)
Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. Later, meta-analysis suggested the link to be secondar
Externí odkaz:
https://doaj.org/article/7b401565bf86409c8aca965e1f509a9d
Publikováno v:
Cancers, Vol 15, Iss 7, p 1929 (2023)
The treatment of multiple myeloma (MM) has greatly evolved these past few years. Recent advances in therapeutics have largely benefited elderly patients now renamed “non-transplant-eligible” (NTE) patients. Since the 1960s, and for several decade
Externí odkaz:
https://doaj.org/article/dd2f2dc1b8c54a109047e683b14b493a
Autor:
Arthur Bobin, Hélène Gardeney, Florence Sabirou, Cécile Gruchet, Anthony Lévy, Laly Nsiala, Laura Cailly, Cécile Tomowiak, Jose Torregrosa, Stéphanie Guidez, Xavier Leleu
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially
Externí odkaz:
https://doaj.org/article/7f54f81057e6408ca0c07d93dc1997ca
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 327-338 (2018)
Vjollca Qerimi,1,2 Aleksandra Kapedanovska Nestorovska,1 Zoran Sterjev,1 Sonja Genadieva-Stavric,3 Ljubica Suturkova1 1Faculty of Pharmacy, Ss. Cyril and Methodius University in Skopje, Skopje, Macedonia; 2Institute of Public Health, Medical Decision
Externí odkaz:
https://doaj.org/article/ee1e1691b5d848fd8d0bfdc849f00e40
Publikováno v:
Cancer Management and Research, Vol Volume 9, Pp 287-298 (2017)
Zi-Hang Zeng,1,2 Jia-Feng Chen,1,2 Yi-Xuan Li,1,2 Ran Zhang,1,2 Ling-Fei Xiao,1,2 Xiang-Yu Meng1,2 1Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, 2Department of Evidence-Based Medicine and Clinical Epide
Externí odkaz:
https://doaj.org/article/19e6bcafe575466eb6c752fb1c883591
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodriguez Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando, Claudio Cerchione, Matteo Da Vià, Niccolò Bolli, Pierpaolo Correale, Francesco Di Raimondo, Massimo Gentile, Jesus San Miguel, Sergio Siragusa
The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3209f8c17435e036f61431ad74639780
https://hdl.handle.net/20.500.11769/542053
https://hdl.handle.net/20.500.11769/542053
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.